American Conference Institute (ACI) will be holding a conference on Pharmaceutical and Biotechnology Patent Life Cycles and Portfolio Strategies on February 26-27, 2014 in New York, NY. ACI faculty will help attendees:
• Apply second generation small molecule patent portfolio management strategies to large molecule patents;
• Understand how safe harbor and 272(e)(1) controversies under Classen and Momenta are impacting pharmaceutical and biotechnology patent portfolio and life cycle management;
• Assess the future of innovation within the confines of new Supreme Court jurisprudence concerning 101 patentability and its implications for diagnostics and other life sciences-related patented inventions;
• Explore new exclusivity concerns over combination products and related Orange Book listing controversies;
• Decipher the implications of the Watson/Activis on long term life cycle planning strategies;
• Weigh the pros and cons of BLA filings vs. biosimilars filings;
• Appreciate how the dichotomy in the Federal Courts and PTO in obvious determinations is influencing patenting strategies for pharmaceutical and biotechnology inventions;
• Examine the relationship between inducement / divided infringement theories and methods of treatment claims in pharmaceutical and biotechnology patents;
• Devise tactics to develop, protect, and enhance antibodies and related technologies;
• Comprehend how new PTO proceedings such as PGR and IPR are influencing prosecution strategies for large and small molecules; and
• Analyze the PTO's new proposed Rules of Professional Conduct.
In particular, ACI's faculty will offer presentations on the following topics:
• Commentary on Developing New Patent Life Cycle and Portfolio Planning Strategies for Small and Large Molecules and Ancillary Technologies in An Evolving IP Landscape
• PTO Keynote: AIA implementation and Its Impact on Pharmaceutical and Biotechnology Patents -- to be presented by Janet Gongola, Associate Commissioner for Patent Examination Policy, U.S. Patent & Trademark Office
• Second Life Molecule Patent Planning Strategies and Tactics: What Large Molecules Can Learn From Small Molecules in Patent Life Cycle Management
• Prometheus and Myriad: Questions of Natural Law and 101 Patentability and Their Implications for Life Sciences Innovation and the Future of Personalized Medicine
• Circumventing the Tempest Which Has Entered the Safe Harbor: IP and R&D Strategies for Pharmaceutical and Biotechnology Patents in the Wake of New 271(e)(1) Controversies
• Biosimilars or BLA: Choosing the Path the Makes the Most IP and Economic Sense for Your Company
• Antitrust Update: The Actavis Fallout and Other New Antitrust Hot Buttons Impacting Patent Life Cycle Strategies in the Biopharmaceutical Industry
• Obviousness In Review: New Developments in the Courts and PTO That May Affect Life Cycle and Patent Portfolio Management in the Pharmaceutical, Biopharmaceutical and Biotechnology Industries
• Strategies for Antibody Patenting in the Wake of Myriad
• Evolving Theories of Inducement and Divided Infringement Concerning Method Treatment Claims and Their Implications for Pharmaceutical and Biotechnology Patents
• Impact of PGR, IPR and Other PTO Proceedings on Life Cycle Planning Strategies for Large and Small Molecules
• Exclusivities: New Developments, Controversies and Concerns for Small Molecules, Large Molecules and Combination Products
• Ethics and Biopharmaceutical IP: An Update on The PTO’s Recent Activity Concerning Ethics and Conduct and Related Matters
Two pre-conference workshops will be offered on February 25, 2014. The first workshop, entitled "'First Inventor to File' Master Class: Successful Strategies for Pharmaceutical, Biopharmaceutical, and Biotechnology Patent Practitioners," will be offered from 8:30 am to 12:00 pm, and the second workshop, entitled "PTA-PTE Boot Camp: Basic Training in the Essentials of Patent Term Adjustment and Patent Term Restoration for Patent Lawyers Serving the Pharmaceutical, Biopharmaceutical, and Biotechnology Industries," will be offered from 2:00 pm until 5:30 pm.
An agenda for the conference can be found here, and additional information regardfing the wrokshops can be found here. A complete brochure for this conference, including an agenda, detailed descriptions of conference sessions, list of speakers, and registration form can be obtained here.
The registration fee is $2,295 (conference alone), $2,895 (conference and workshop), or $3,495 (conference and both workshops). Those registering by January 6, 2014 will receive a $300 discount and those registering by February 3, 2014 will receive a $200 discount. Those interested in registering for the conference can do so here, by e-mailing [email protected], by calling 1-888-224-2480, or by faxing a registration form to 1-877-927-1563.
Patent Docs is a media partner of ACI's Pharmaceutical and Biotechnology Patent Life Cycles and Portfolio Strategies conference.
Comments